Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective To evaluate the interval between the onset of detectable cognitive impairment and clinical diagnosis in individuals with probable Alzheimer's disease (AD), and to identify the pattern of the earliest changes in cognition in probable AD. Design Longitudinal follow-up of a community-based cohort sample. In 1976 through 1978, a screening neuropsychological examination was administered to Framingham Study participants. These subjects were then followed up prospectively for development of probable AD for up to 13 years. Setting This study was conducted at a community-based center for epidemiologic research. Participants The surveillance sample consisted of 1045 participants in the Framingham Study aged 65 to 88 years who were free of dementia at the time of the neuropsychological screening examination. Main outcome measures Scores on a group of neuropsychological tests were entered into a series of age- and education-adjusted multiple regression procedures, with the presence or absence of probable AD as the outcome variable. Results Considered individually, most of the screening neuropsychological measures were significantly related to later AD diagnosis. When stepwise regression procedures were employed, only measures of verbal memory and immediate auditory attention span remained significantly related to AD diagnosis. Of note, subjects later diagnosed with probable AD performed at higher levels than normal subjects on the Digit Span test at initial screening. Regression results were essentially unchanged even when the AD sample was restricted to those individuals for whom the screening examination preceded the clinical onset of dementia by 7 years or more. Conclusions These findings support previous contentions that a "preclinical phase" of detectable cognitive deficits can precede the clinical diagnosis of probable AD by many years, and they also support the hypothesis that problems with secondary verbal memory are among the first signs of AD.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 1,045 participants. In this 13-year prospective study, most screening neuropsychological measures were individually related to later Alzheimer's disease diagnosis, but only measures of verbal memory and immediate auditory attention span remained significantly related in stepwise regression. The results suggest cognitive changes can be detected years before clinical diagnosis, which may help identify people early, but the study reports no treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Linn, R. T., Wolf, P. A., Bachman, D. L., Knoefel, J. E., Cobb, J. L., Belanger, A. J., et al. (1995). The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Archives of neurology. https://doi.org/10.1001/archneur.1995.00540290075020

Vancouver

Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, et al. The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Archives of neurology. 1995. doi:10.1001/archneur.1995.00540290075020. PMID: 7733843.

BibTeX

@article{linn1995-7733843,
  author  = {Linn, R. T. and Wolf, P. A. and Bachman, D. L. and Knoefel, J. E. and Cobb, J. L. and Belanger, A. J. and Kaplan, E. F. and D'Agostino, R. B.},
  title   = {{The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort}},
  journal = {Archives of neurology},
  year    = {1995},
  doi     = {10.1001/archneur.1995.00540290075020},
  pmid    = {7733843},
  url     = {https://doi.org/10.1001/archneur.1995.00540290075020}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In this 13-year prospective study, most screening neuropsychological measures were individually related to later Alzheimer's disease diagnosis, but only measures of verbal memory and immediate auditory attention span remained significantly related in stepwise regression. The results suggest cognitive changes can be detected years before clinical diagnosis, which may help identify people early, but the study reports no treatment or cure.

Study details

How this study scored 60/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 4 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 58 of the 97 points it could be judged on, which is 60 of 100. Total 60 of 100.58 of the 97 points we could judge = 60 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 58 of the 97 points we could judge it on, which is 60 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Archives of neurology)
Journal's citation record 3 / 4 Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1995 — older than 20 years, still counted
Sample size 3 / 4 1,045 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 437 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 13.2 citations a year over 33 year(s) since 1995
Impact for its field and year 3 / 6 Cited 7.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 33 other studies in this library
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Richard T. Linn: h-index 27 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 7733843)
Free to read 0 / 2 Behind a paywall — scores zero
Points 58 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 97 points we could judge it on is 60 out of 100.
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

33 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also in Getting a diagnosis

141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →